Suppression of murine endotoxic shock by sPLA2 inhibitor, indoxam, through group IIA sPLA2-independent mechanisms

Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids

Volumn 1438, Issue 2, 1999, Pages 213-222

  Yokota, Yasunori ^a   Hanasaki, Kohji ^a   Ono, Takashi ^a   Nakazato, Hitoshi ^a   Kobayashi, Tatsuo ^a   Arita, Hitoshi ^a  

^a SHIONOGI AND CO LTD   (Japan)

Author keywords

Endotoxic shock; Inhibitor; Phospholipase A2; Phospholipase A2 receptor; Tumor necrosis factor

Indexed keywords

INTERLEUKIN 1BETA; INTERLEUKIN 6; ISOENZYME; LIPOPOLYSACCHARIDE; PHOSPHOLIPASE A2; PHOSPHOLIPASE A2 INHIBITOR; TRIACYLGLYCEROL LIPASE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE RESISTANCE; ENZYME INHIBITION; FEMALE; IN VITRO STUDY; INTRAPERITONEAL DRUG ADMINISTRATION; LETHALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEPTIC SHOCK;

ANIMALS; CARBAMATES; CARRIER PROTEINS; ENZYME INHIBITORS; FEMALE; INDOLIZINES; INTERLEUKIN-1; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; PHOSPHOLIPASES A; RECEPTORS, CELL SURFACE; SHOCK, SEPTIC; TUMOR NECROSIS FACTOR-ALPHA;

MURINAE;

EID: 0032940930     PISSN: 13881981     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1388-1981(99)00053-0     Document Type: Article

References (52)

1. 2 in the pathobiology of disease. Lab. Invest. 55:1986;391-404.
2. 2: its generation and role in platelet activation. Prog. Lipid Res. 28:1989;273-301.
3. 2. J. Biol. Chem. 269:1994;13057-13060.
4. 2 superfamily of signal transduction enzymes. Trends Biochem. Sci. 22:1997;1-2.
5. 2 gene family in mammals. J. Biol. Chem. 272:1997;17247-17250.
6. 2. J. Biol. Chem. 272:1997;15745-15752.
7. 2. Biochim. Biophys. Acta. 117:1993;217-231.
8. 2 receptor-deficient mice. J. Biol. Chem. 272:1997;32792-32797.
9. de Haas G.H., Postema N.M., Nieuwenhuizen W., van Deenen L.L.M. Purification and properties of an anionic zymogen of phospholipase A from porcine pancreas. Biochim. Biophys. Acta. 159:1968;118-129.
10. 2 in Swiss 3T3 cells via specific binding site. J. Biol. Chem. 266:1991;19139-19141.
11. 2 via its high affinity receptor stimulates extracellular matrix invasion by normal and cancer cells. J. Biol. Chem. 272:1997;2346-2353.
12. 2 via specific binding sites. Biochim. Biophys. Acta. 1125:1992;210-214.
13. 2 on isolated porcine cerebral arteries via its specific binding sites. FEBS Lett. 309:1992;261-264.
14. 2 in rat ovaries: stimulatory action on progesterone release. Endocrinology. 135:1994;603-609.
15. 2 receptor. J. Biol. Chem. 269:1994;5897-5904.
16. 2. J. Biol. Chem. 269:1994;1575-1578.
17. 2. J. Biol. Chem. 270:1995;8963-8970.
18. 2 receptor. Prog. Lipid Res. 34:1995;117-138.
19. 2 receptors from various mammals. Eur. J. Biochem. 225:1994;375-382.
20. 2 levels with circulatory collapse. Crit. Care Med. 16:1988;1-7.
21. 2 levels: correlation with hemodynamic and pulmonary changes in Gram-negative septic shock. J. Lab. Clin. Med. 104:1984;873-881.
22. 2 in serum and pulmonary and renal complications in acute pancreatitis. Digestion. 52:1992;232-236.
23. 2 activity associated with sepsis and septic shock is indistinguishable from that associated with rheumatoid arthritis. Inflammation. 15:1991;355-367.
24. 2 in cartilage. J. Rheumatol. 20:1993;325-330.
25. 2. Annu. Rep. Med. Chem. 24:1989;157-166.
26. Sofia M.J., Silbough S.A. Novel approaches to anti-inflammatory agents as therapeutics for pulmonary disease. Annu. Rep. Med. Chem. 28:1993;109-118.
27. 2 inhibitors. Drugs Future. 15:1990;139-148.
28. 2. Nat. Struct. Biol. 2:1995;458-465.
29. Min-induced intestinal neoplasia. Cell. 81:1995;957-966.
30. 2 gene in inbred mouse strains. J. Biol. Chem. 270:1995;22378-22385.
31. 2 generation in mouse bone-marrow-derived mast cells. J. Biol. Chem. 271:1996;25936-25944.
32. 2 in transgenic mice results in epidermal hyperplasia in the absence of inflammatory infiltrate. J. Clin. Invest. 97:1996;2233-2241.
33. 2: synthesis and inhibitory activities of indollizine and indene derivatives. J. Med. Chem. 39:1996;3636-3658.
34. 2 isozymes. J. Lipid Res. 34:1993;837-844.
35. 2 is a 100-kDa protein in human monoblast U937 cells. J. Biol. Chem. 266:1991;5268-5272.
36. 2+ mobilization through its specific receptors in murine peritoneal macrophages. FEBS Lett. 280:1991;103-106.
37. Isshiki H., Akira S., Tanabe O., Nakajima T., Shimamoto T., Hirano T., Kishimoto T. Constitutive and Interleukin-1 (IL-1)-inducible factors interact with the IL-1-responsive element in the IL-6 gene. Mol. Cell. Biol. 10:1990;2757-2764.
38. 2 in the rat. J. Biol. Chem. 267:1992;6414-6420.
39. 2 stimulates prostaglandin synthesis in mouse osteoblastic cells (MC3T3-E1) via a specific binding site. J. Biol. Chem. 268:1993;2865-2871.
40. 50) of an enzymatic reaction. Biochem. Pharmacol. 22:1973;3099-3108.
41. Kitadokoro K., Hagishita S., Sato T., Ohtani M., Miki K. Crystal structure of human secretory phospholipase A2-IIA complex with the potent indolizine inhibitor 120-1032. J. Biochem. 123:1998;619-623.
42. Morrison D.C., Ryan J.L. Endotoxins and disease mechanisms. Annu. Rev. Med. 38:1987;417-432.
43. 2 enzymes: regulation and physiological role. Biochem. Pharmacol. 48:1994;1-10.
44. 2 into receptor binding, active form. Biochem. Biophys. Res. Commun. 198:1994;10-15.
45. 2 propeptide immunoreactivity is released from activated granulocytes. Clin. Biochem. 28:1995;71-78.
46. 2 propeptide in acute lung injury. Lancet. 344:1994;1472-1473.
47. 2 via its specific binding site. FEBS Lett. 303:1992;217-220.
48. 2. Biochim. Biophys. Acta. 1393:1998;253-266.
49. 2. J. Biol. Chem. 269:1994;2365-2368.
50. 1 macrophages. J. Biol. Chem. 271:1996;32381-32384.
51. 2 that mediates prostaglandin production in mast cells. J. Biol. Chem. 272:1997;13591-13596.
52. 2 expression and pathogenesis of the sepsis syndrome. Circ. Shock. 39:1993;160-167.